Takeda, M., Okamoto, I., Yamanaka, T., Nakagawa, K., & Nakanishi, Y. (2012). Impact of treatment with bevacizumab beyond disease progression: A randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non–small cell lung cancer (WJOG 5910L). BioMed Central.

Takeda, Masayuki, Isamu Okamoto, Takeharu Yamanaka, Kazuhiko Nakagawa, och Yoichi Nakanishi. Impact of Treatment With Bevacizumab Beyond Disease Progression: A Randomized Phase II Study of Docetaxel With or Without Bevacizumab After Platinum-based Chemotherapy Plus Bevacizumab in Patients With Advanced Nonsquamous Non–small Cell Lung Cancer (WJOG 5910L). BioMed Central, 2012.

Takeda, Masayuki, et al. Impact of Treatment With Bevacizumab Beyond Disease Progression: A Randomized Phase II Study of Docetaxel With or Without Bevacizumab After Platinum-based Chemotherapy Plus Bevacizumab in Patients With Advanced Nonsquamous Non–small Cell Lung Cancer (WJOG 5910L). BioMed Central, 2012.